IKT
Inhibikase Therapeutics Inc

1,960
Mkt Cap
$248.6M
Volume
242,481.00
52W High
$2.58
52W Low
$1.33
PE Ratio
-3.59
IKT Fundamentals
Price
$1.98
Prev Close
$2.05
Open
$1.95
50D MA
$1.75
Beta
1.05
Avg. Volume
519,219.10
EPS (Annual)
-$1.16
P/B
2.10
Rev/Employee
$0.00
$20.37
Loading...
Loading...
News
all
press releases
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital
Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% - Still a Buy?
Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.4% - Time to Buy...
MarketBeat·4d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating
Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat·5d ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings...
MarketBeat·15d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9% - Time to Buy?
Inhibikase Therapeutics (NASDAQ:IKT) Trading 6.9% Higher - Still a Buy...
MarketBeat·18d ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America
Bank of America initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat reports...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2% - What's Next?
Inhibikase Therapeutics (NYSE:IKT) Shares Up 1.2% - What's Next...
MarketBeat·1mo ago
News Placeholder
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0%
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling...
MarketBeat·2mo ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...
MarketBeat·2mo ago
<
1
2
...
>

Latest IKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.